JP2553258B2 - Method for producing wax-coated preparation - Google Patents
Method for producing wax-coated preparationInfo
- Publication number
- JP2553258B2 JP2553258B2 JP3143786A JP14378691A JP2553258B2 JP 2553258 B2 JP2553258 B2 JP 2553258B2 JP 3143786 A JP3143786 A JP 3143786A JP 14378691 A JP14378691 A JP 14378691A JP 2553258 B2 JP2553258 B2 JP 2553258B2
- Authority
- JP
- Japan
- Prior art keywords
- coating
- waxes
- wax
- solvent
- core substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000011248 coating agent Substances 0.000 claims description 39
- 238000000576 coating method Methods 0.000 claims description 35
- 239000001993 wax Substances 0.000 claims description 27
- 239000002245 particle Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000010409 thin film Substances 0.000 claims description 4
- -1 fatty acid glycerin esters Chemical class 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 238000009834 vaporization Methods 0.000 claims description 2
- 230000008016 vaporization Effects 0.000 claims description 2
- 238000000151 deposition Methods 0.000 claims 1
- 239000011162 core material Substances 0.000 description 16
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 8
- 239000010419 fine particle Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000005054 agglomeration Methods 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- 229960000278 theophylline Drugs 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229920001268 Cholestyramine Polymers 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical group C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、薬剤の表面にワックス
類をコーティングしてなるワックス被覆製剤の製造方法
に関するものであり、特にマイクロカプセル、細粒等微
細な粒子のコーティングに好適な製造方法を提供するも
のである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing a wax-coated preparation in which the surface of a drug is coated with waxes, and is particularly suitable for coating fine particles such as microcapsules and fine particles. Is provided.
【0002】[0002]
【従来の技術】従来、ワックス被覆製剤の製造方法とし
ては、剤皮を施していない固形製剤にワックス類を流動
層を用いて熱処理する方法(特開平1−287021号
公報)、ワックス類を有機溶媒と水の混合溶媒に溶解
し、芯物質を浸漬させた後、溶媒を除去するもの(特開
昭63−151353号公報)等が知られているが、温
度の制御が難しく微粒子のコーティングが不可能であ
る、工程が煩雑である、芯物質が溶媒に溶解する場合に
は適用できない等の欠点があった。2. Description of the Related Art Conventionally, as a method for producing a wax-coated preparation, a method of heat-treating waxes in a solid preparation not coated with a fluidized bed (Japanese Patent Laid-Open No. 1-287021) and organic waxes are used. It is known to dissolve the solvent in a mixed solvent of water and water, immerse the core substance, and then remove the solvent (Japanese Patent Laid-Open No. 63-151353), but it is difficult to control the temperature and coating of fine particles is difficult. It has the drawbacks that it is impossible, the process is complicated, and it cannot be applied when the core substance is dissolved in a solvent.
【0003】[0003]
【発明が解決しようとする課題】ワックス類を微細な粒
子の表面にコーティングする場合、ワックス自身の融点
が低い事から粒子同志の凝集が生じやすく、微細なまま
コーティングを行い粒子表面に緻密な薄膜を施すのは非
常に困難であった。粒子同志の凝集は、芯物質に付着し
たコーティング剤が乾ききらず、粘着性を保っているた
め起こる現象である。従って芯物質に付着したコーティ
ング剤の粘着性を急激に下げれば凝集を防ぐことが可能
となる。この点に着目し、微細な粒子の表面に直接コー
ティングすることを目的として鋭意検討した結果、粒子
同志の凝集なしに微細粒子のコーティングが可能な本発
明を見い出した。When waxes are coated on the surface of fine particles, the melting point of the wax itself is low, so that agglomeration of the particles is likely to occur. It was very difficult to apply. Agglomeration of particles is a phenomenon that occurs because the coating agent attached to the core substance does not dry out and maintains its tackiness. Therefore, agglomeration can be prevented by rapidly reducing the adhesiveness of the coating agent attached to the core substance. Focusing on this point, as a result of intensive studies aimed at directly coating the surface of fine particles, the present invention has found that fine particles can be coated without agglomeration of particles.
【0004】[0004]
【課題を解決するための手段】即ち、本発明の要旨は、
少なくとも1種類以上のワックス類を含有するコーティ
ング原料を溶媒に加温溶解し、該コーティング溶液を芯
物質となる粒子表面に芯物質の温度40℃以下でスプレ
ーし、スプレー前後におけるコーティング溶液の温度差
及び溶媒の蒸発潜熱によりコーティング溶液中のワック
ス類の溶解度を低下させ、粒子表面にワックス類を析出
せしめると同時に薄膜を形成させることを特徴とする、
ワックス被覆製剤の製造方法に存する。That is, the gist of the present invention is as follows.
A coating raw material containing at least one or more waxes is dissolved in a solvent by heating, and the coating solution is sprayed on the surface of particles serving as a core substance at a temperature of the core substance of 40 ° C. or less, and the temperature difference of the coating solution before and after spraying
And wack in coating solution due to latent heat of vaporization of solvent
Decrease the solubility of waxes and deposit waxes on the particle surface
It is characterized by forming a thin film at the same time as
It exists in a method for producing a wax-coated preparation.
【0005】本発明の方法によれば、コーティング原料
を溶媒に加温溶解して、芯物質となる粒子表面に芯物質
の温度40℃以下でスプレーすることで、粒子表面に急
激にコーティング原料を析出させるので溶媒の蒸発潜熱
により、コーティング原料の温度が急激に下がり、同時
に溶解度も低下し、粒子表面にワックス類が到達した瞬
間これらが析出し、薄膜を形成する。この方法によれ
ば、粒子同志の凝集を極力抑えつつ微細な粒子のコーテ
ィングが可能である。According to the method of the present invention, the coating raw material is dissolved in a solvent by heating and sprayed onto the surface of the particle serving as the core material at a temperature of 40 ° C. or lower, so that the coating material is rapidly coated on the surface of the particle. Because of the precipitation, the latent heat of evaporation of the solvent causes the temperature of the coating material to drop sharply, and at the same time, the solubility to decrease, and at the moment when the waxes reach the surface of the particles, these deposit and form a thin film. According to this method, it is possible to coat fine particles while suppressing the aggregation of particles.
【0006】本発明においては、コーティング原料とは
ワックス類あるいはワックス類及びコーティング剤の混
合物を表わす。又、本発明で用いるワックス類として
は、ステアリン酸、カプリン酸、ラウリン酸、ミリスチ
ン酸、パルミチン酸、ウンデカン酸等の脂肪酸;ラウリ
ルアルコール、ミリスチルアルコール、セチルアルコー
ル、ステアリルアルコール、ウンデカノール等の高級ア
ルコールまたはステアリン、ミリスチン、パルミチン、
ラウリン等の脂肪酸グリセリンエステル等が挙げられ
る。これらのワックス類を1種あるいは2種以上組み合
わせて使用する。さらに、エチルセルロース、ヒドロキ
シプロピルセルロース、カルボキシメチルエチルセルロ
ース等の通常用いられるコーティング剤を上記のワック
ス類に混合して用いることも可能である。In the present invention, the coating raw material means waxes or a mixture of waxes and coating agents. The waxes used in the present invention include fatty acids such as stearic acid, capric acid, lauric acid, myristic acid, palmitic acid, and undecanoic acid; higher alcohols such as lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, and undecanol. Stearin, myristin, palmitin,
Examples thereof include fatty acid glycerin esters such as laurin. These waxes are used alone or in combination of two or more. Furthermore, it is also possible to use a commonly used coating agent such as ethyl cellulose, hydroxypropyl cellulose, carboxymethyl ethyl cellulose, etc. by mixing with the above waxes.
【0007】本発明における溶媒は、ワックス類を含む
コーティング原料を加温溶解しえるものであれば使用す
る事ができるが、作業環境等を考慮すると塩素系の溶媒
は好ましくなく、メタノール、エタノール、プロパノー
ル、アセトン、メチルエチルケトン等が好ましい。又、
ワックス類の濃度は溶媒に対する溶解度により適宜調節
できるが、本発明方法によれば、50%以上の高濃度で
も粒子同志の凝集は起こらず、短時間でのコーティング
が可能である。スプレー時の芯物質の温度は40℃以下
であり、40℃を超えると徐々に粒子同志の凝集が生ず
るので好ましくない。通常15〜35℃で行うのが作業
上適している。The solvent in the present invention can be used as long as it can dissolve the coating materials containing waxes under heating, but a chlorine-based solvent is not preferable in consideration of the working environment, and methanol, ethanol, Propanol, acetone, methyl ethyl ketone and the like are preferable. or,
The concentration of the waxes can be adjusted appropriately depending on the solubility in the solvent, but according to the method of the present invention, even if the concentration is 50% or more, the aggregation of the particles does not occur, and the coating can be performed in a short time. The temperature of the core substance during spraying is 40 ° C. or lower, and if it exceeds 40 ° C., the particles are gradually aggregated, which is not preferable. Usually, it is suitable to carry out at 15 to 35 ° C.
【0008】本発明の方法ではコーティング溶液をスプ
レーと同時に粒子表面に析出させ、薄膜を形成させるた
め、本発明に用いるコーティング装置としては、直接芯
物質へのスプレーが可能なサイドスプレー式やボトムス
プレー式の装置が好ましく、例えば流動層造粒コーティ
ング装置、旋回型流動層造粒コーティング装置、遠心流
動型造粒コーティング装置等が挙げられる。In the method of the present invention, since the coating solution is simultaneously sprayed and deposited on the surface of the particles to form a thin film, the coating apparatus used in the present invention is a side spray type or bottom spray type capable of directly spraying the core substance. Type apparatus is preferable, and examples thereof include a fluidized bed granulation coating apparatus, a swirl type fluidized bed granulation coating apparatus, and a centrifugal fluidized type granulation coating apparatus.
【0009】本発明で使用する芯物質の粒径に特に制限
はないが、数十ミクロン〜5mmのものが好ましく、特に
コーティングが難しいとされる数十ミクロンの粒子でも
凝集はわずかであり、コーティングが可能である。本発
明の製剤の一般的製造方法としては、芯物質をコーティ
ング装置に仕込み、所定量のコーティング原料を秤量
し、溶媒を加えた後、加温溶解する(コーティング溶液
の作成)。次に芯物質を40℃以下で(通常室温で可)
流動あるいは転動させながら、コーティング溶液をスプ
レーする。スプレー終了後、乾燥を行なう。The particle size of the core substance used in the present invention is not particularly limited, but it is preferably several tens of microns to 5 mm, and even particles of several tens of microns, which are considered to be particularly difficult to coat, have a small amount of agglomeration. Is possible. As a general method for producing the preparation of the present invention, a core material is charged into a coating apparatus, a predetermined amount of coating raw material is weighed, a solvent is added, and then dissolved by heating (preparation of coating solution). Next, the core substance is kept at 40 ° C or lower (usually at room temperature)
Spray the coating solution while flowing or tumbling. After spraying, dry.
【0010】[0010]
【実施例】次に本発明を実施例に基づき、更に詳細に説
明するが、その要旨を越えない限り、本発明はこれら実
施例に限られるものではない。 実施例1 粒径が凡そ10〜40ミクロンの無水テオフィリンを用
い苦みのマスキングを行った。テオフィリンは鎮咳去痰
剤として知られているが、一方かなり強い苦みを有する
化合物として知られている。以下に方法と結果を示す。
無水テオフィリン3kgをスーパー造粒コーティング装置
(フロイント産業社製、SFC−5)に仕込む。グリセ
リンモノステアレート2.0kg、及びステアリン酸1.
0kgにエタノール3kgを加えて加温溶解し、以下の様な
条件でコーティングを行なう。途中、芯物質に対し、コ
ーティング量が25%、50%、75%、100%に達
したところで経時的にサンプリングを行い苦み試験及び
顕鏡を行った(芯物質100部に、コーティング液10
0部がコーティングされた状態を100%とする。)。
結果を表−1に示す。The present invention will be described in more detail based on the following examples, but the present invention is not limited to these examples as long as the gist thereof is not exceeded. Example 1 Bitterness masking was performed using anhydrous theophylline having a particle size of approximately 10 to 40 microns. Theophylline is known as an antitussive expectorant, while it is known as a compound with a rather strong bitterness. The method and results are shown below.
3 kg of anhydrous theophylline is charged into a super granulation coating device (SFC-5, manufactured by Freund Sangyo Co., Ltd.). Glycerin monostearate 2.0 kg, and stearic acid 1.
Ethanol (3 kg) is added to 0 kg to dissolve by heating, and coating is performed under the following conditions. On the way, when the coating amount reached 25%, 50%, 75%, and 100% with respect to the core substance, sampling was performed over time to perform a bitterness test and a microscope (100 parts of the core substance, 10 parts of the coating liquid 10
The state where 0 part is coated is 100%. ).
The results are shown in Table 1.
【0011】 吸気温度 20〜30℃ (室温) 芯物質温度 20〜25℃ スプレー流量 30g /min ローター回転数 150rpm アギテーター回転数 150rpm 噴霧圧 3kg 苦み試験結果Intake temperature 20 to 30 ° C. (room temperature) Core substance temperature 20 to 25 ° C. Spray flow rate 30 g / min Rotor speed 150 rpm Aggitator speed 150 rpm Spray pressure 3 kg Bitterness test result
【0012】[0012]
【表1】 苦みの判定は以下の基準にしたがって行った。 評価基準; 3 苦くて耐えられ無い 2 かなり苦い 1 やや苦いと感じる 0 苦く無い[Table 1] The bitterness was determined according to the following criteria. Evaluation criteria; 3 Unbearable 2 Unbearable 1 Feeling slightly bitter 0 Not bitter
【0013】上記の結果から、芯物質に対し、50%の
コーティング量でほぼ苦みが消失する事が分かる。次に
顕鏡の結果を図−1及び図−2の写真に示す。(最小目
盛り10ミクロン)顕鏡の結果から10〜40ミクロン
のテオフィリン100%に対し、ワックスを50%コー
ティングしても、最も大きい粒子の粒径は、70ミクロ
ン程度となっており、凝集等が非常に少ない事がわか
る。この方法によればこれまで非常に困難であった苦み
の強い細粒剤等のマスキングを原体の段階で行う事が可
能となる。From the above results, it can be seen that bitterness disappears at a coating amount of 50% with respect to the core substance. Next, the results of the microscope are shown in the photographs of FIGS. 1 and 2. (Minimum scale: 10 microns) From the result of a microscope, even if 50% of wax is coated on 100% of theophylline of 10 to 40 microns, the largest particle size is about 70 microns, and agglomeration etc. You can see that there are very few. According to this method, it becomes possible to perform masking of fine granules having a strong bitterness, which has been very difficult until now, at the stage of the drug substance .
【0014】実施例2 コレスチラミンにワックスコーティングを行い、服用時
膨潤の少ない顆粒剤を製造した。コレスチラミンは動脈
硬化用剤として知られているが、イオン交換樹脂である
為、吸水しやすく吸水すると、著しく膨潤する。したが
って現在剤形としては、用時水に懸濁して用いるドライ
シロップのみが市販されている。スーパー造粒コーティ
ング装置(フロイント産業社製、SFC−5)にコレス
チラミン3kgを仕込む。グリセリンモノステアレート
0.3kgをエタノール0.3kgに加温溶解し、実施例1
と同様な条件でコーティングを行なった。コーティング
末3kgにヒドロキシプロピルセルロース0.3kgを加
え、混合後エタノール0.8kgを加え練合し、0.8mm
径のスクリーンをつけた円筒造粒機でおしだす。棚乾燥
を行った後、整粒し、篩過する。Example 2 Cholestyramine was coated with wax to prepare granules with little swelling when ingested. Cholestyramine is known as an arteriosclerosis agent, but since it is an ion exchange resin, it easily absorbs water and swells significantly when it absorbs water. Therefore, as the present dosage form, only dry syrup which is suspended in water before use is commercially available. Charge 3kg of cholestyramine into a super granulation coating device (SFC-5, manufactured by Freund Sangyo). Glycerin monostearate (0.3 kg) was dissolved in ethanol (0.3 kg) with heating to give Example 1.
Coating was performed under the same conditions as in. 0.3 kg of hydroxypropyl cellulose was added to 3 kg of coating powder, 0.8 kg of ethanol was added after mixing, and kneaded to 0.8 mm
Start with a cylindrical granulator equipped with a diameter screen. After shelf drying, the particles are sized and sieved.
【0015】更にこの素顆粒3kgにグリセリンモノステ
アレート0.15kg及びエチルセルロース0.15kgを
エタノール1.2kgに加温溶解したものを用い実施例1
と同様な条件でコーティングした。コーティング顆粒に
ラウリル硫酸ナトリウムを0.2%加え服用性の良い顆
粒剤を得た。この顆粒剤は25℃相対湿度75%の条件
下、3ケ月放置しても外観に変化なく安定であった。Further, 0.13 kg of glycerin monostearate and 0.15 kg of ethyl cellulose were dissolved in 1.2 kg of ethanol under heating to 3 kg of the elementary granules.
Coating was performed under the same conditions as in. Sodium lauryl sulfate was added to the coated granules in an amount of 0.2% to obtain granules with good ingestibility. The granules were stable under the conditions of 25 ° C. and 75% relative humidity even after being left for 3 months without any change in appearance.
【0016】[0016]
【発明の効果】本発明によれば、微細粒子のコーティン
グが可能になる為、薬剤を原体のままコーティングし、
それを種々の剤型に加工できるので幅広いコーティング
製剤が提供できる。EFFECTS OF THE INVENTION According to the present invention, it becomes possible to coat fine particles.
Since it can be processed into various dosage forms, a wide range of coating preparations can be provided.
【図1】テオフィリン原体の顕微鏡写真(×100)で
あり、写真中の1目盛りは10ミクロンを表わす。FIG. 1 is a micrograph (× 100) of theophylline drug substance, and one scale in the photograph represents 10 microns.
【図2】50%コーティングテオフィリン末の顕微鏡写
真(×100)であり、写真中の1目盛りは10ミクロ
ンを表わす。FIG. 2 is a photomicrograph (× 100) of 50% coated theophylline powder, where 1 scale represents 10 microns.
Claims (2)
有するコーティング原料を溶媒に加温溶解し、該コーテ
ィング溶液を芯物質となる粒子表面に芯物質の温度40
℃以下でスプレーし、スプレー前後におけるコーティン
グ溶液の温度差及び溶媒の蒸発潜熱によりコーティング
溶液中のワックス類の溶解度を低下させ、粒子表面にワ
ックス類を析出せしめると同時に薄膜を形成させること
を特徴とする、ワックス被覆製剤の製造方法。1. A coating raw material containing at least one or more waxes is dissolved in a solvent by heating, and the coating solution is applied to the surface of particles to be the core substance at a temperature of the core substance 40.
Spray below ℃ , before and after spraying
Coating due to temperature difference of solution and latent heat of vaporization of solvent
It reduces the solubility of waxes in the solution and causes the wax on the particle surface.
To form a thin film at the same time as depositing
A method for producing a wax-coated preparation, comprising:
及び脂肪酸グリセリンエステルから選ばれることを特徴
とする請求項1記載のワックス被覆製剤の製造方法。2. The method for producing a wax-coated preparation according to claim 1, wherein the waxes are selected from fatty acids, higher alcohols and fatty acid glycerin esters.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3143786A JP2553258B2 (en) | 1991-05-20 | 1991-05-20 | Method for producing wax-coated preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3143786A JP2553258B2 (en) | 1991-05-20 | 1991-05-20 | Method for producing wax-coated preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04342523A JPH04342523A (en) | 1992-11-30 |
| JP2553258B2 true JP2553258B2 (en) | 1996-11-13 |
Family
ID=15346969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3143786A Expired - Lifetime JP2553258B2 (en) | 1991-05-20 | 1991-05-20 | Method for producing wax-coated preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2553258B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753904B1 (en) | 1996-10-01 | 1998-10-30 | Gattefosse Ets Sa | PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE OF ACTIVE SUBSTANCE, INCLUDING A MATRIX, AND MANUFACTURING PROCESS |
| WO2003004001A1 (en) * | 2001-07-06 | 2003-01-16 | Lifecycle Pharma A/S | Controlled agglomeration |
| WO2005074959A1 (en) | 2004-02-05 | 2005-08-18 | Access Business Group International Llc | Anti-allergy composition and related method |
| JP2008013480A (en) * | 2006-07-05 | 2008-01-24 | Sawai Pharmaceutical Co Ltd | Drug-containing micro-particle and method for producing the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63151353A (en) * | 1986-12-15 | 1988-06-23 | Oogawara Kakoki Kk | Preparation of wax-coated microcapsule |
-
1991
- 1991-05-20 JP JP3143786A patent/JP2553258B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04342523A (en) | 1992-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2538134B2 (en) | Sustained release preparation and method for producing the same | |
| RS29104A (en) | Powder processing with pressurized gaseous fluids | |
| JP3987282B2 (en) | Particles coated with granulated crystalline ibuprofen | |
| JP2002511402A (en) | Hygroscopic microcapsules having a core coated with a hydrophobic polymer | |
| WO1998010756A1 (en) | Sustained-release preparation utilizing thermal change and process for the production thereof | |
| JPH02258719A (en) | Production of granule | |
| JPS63151353A (en) | Preparation of wax-coated microcapsule | |
| JPH0296516A (en) | Granule and production thereof | |
| JP3247511B2 (en) | Pharmaceutical composition | |
| CA2634481A1 (en) | Masking the taste of powders | |
| WO1997003656A1 (en) | Granular preparation and process for producing the same | |
| JP2553258B2 (en) | Method for producing wax-coated preparation | |
| Takeuchi et al. | Controlled release theophylline tablet with acrylic polymers prepared by spray-drying technique in aqueous system | |
| US5837291A (en) | Enteric preparation coated with a non-solvent enteric coating agent using a liquid plasticizer | |
| JP2004339162A (en) | Pharmaceutical solid preparation containing poorly soluble drug and method for producing the same | |
| JP3130058B2 (en) | Masked granules | |
| Ibrahim et al. | Dissolution characteristics of interactive powder mixtures. Part one: Effect of solubility and particle size of excipients | |
| JPS6335526A (en) | Polymer treated ion exchange resin | |
| JPH04283520A (en) | Spherical nuclei and spherical granule | |
| WO2000018372A1 (en) | Grains for oral preparations | |
| JP5042447B2 (en) | Mixed preparation | |
| JP2987813B2 (en) | Wax-coated preparation and its production method | |
| JPH11349473A (en) | Taste-masked pharmaceutical preparation | |
| KR20070030879A (en) | Oral formulations and methods of making the same | |
| JPH08333238A (en) | Enteric coated drug coated with solvent-free enteric coating agent using liquid wax |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070822 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080822 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090822 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100822 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100822 Year of fee payment: 14 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100822 Year of fee payment: 14 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100822 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110822 Year of fee payment: 15 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110822 Year of fee payment: 15 |